These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31152966)

  • 21. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple sclerosis, a treatable disease .
    Doshi A; Chataway J
    Clin Med (Lond); 2017 Dec; 17(6):530-536. PubMed ID: 29196354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis.
    Bar-Or A
    Exp Neurol; 2014 Dec; 262 Pt A():57-65. PubMed ID: 24925677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study.
    Vieira MC; Conway D; Cox GM; Peeples M; Bensimon AG; Macheca M; Herrera V
    Curr Med Res Opin; 2020 Feb; 36(2):261-270. PubMed ID: 31694401
    [No Abstract]   [Full Text] [Related]  

  • 25. Teriflunomide for the treatment of multiple sclerosis.
    Warnke C; Stüve O; Kieseier BC
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S90-4. PubMed ID: 24321165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity.
    Varytė G; Zakarevičienė J; Ramašauskaitė D; Laužikienė D; Arlauskienė A
    Medicina (Kaunas); 2020 Jan; 56(2):. PubMed ID: 31973138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effector and regulatory B cells in Multiple Sclerosis.
    Staun-Ram E; Miller A
    Clin Immunol; 2017 Nov; 184():11-25. PubMed ID: 28461106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.
    Rommer PS; Zettl UK
    Expert Opin Pharmacother; 2018 Apr; 19(5):483-498. PubMed ID: 29528247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
    Brunetti L; Wagner ML; Maroney M; Ryan M
    Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
    Zagmutt FJ; Carroll CA
    Int J Neurosci; 2015; 125(11):798-807. PubMed ID: 25387069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Newer agents in the treatment of multiple sclerosis.
    Pawate S; Bagnato F
    Neurologist; 2015 Apr; 19(4):104-17. PubMed ID: 25888198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis and trials of clinically isolated syndrome.
    Montalban X; Sastre-Garriga J
    Lancet Neurol; 2014 Oct; 13(10):962-3. PubMed ID: 25192850
    [No Abstract]   [Full Text] [Related]  

  • 35. Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Ingwersen J; Aktas O; Hartung HP
    Neurotherapeutics; 2016 Jan; 13(1):47-57. PubMed ID: 26701666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study.
    Buron MD; Kalincik T; Sellebjerg F; Sørensen PS; Magyari M
    J Neurol Neurosurg Psychiatry; 2021 May; 92(5):556-562. PubMed ID: 33436501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease modifying therapies for relapsing multiple sclerosis.
    Wingerchuk DM; Weinshenker BG
    BMJ; 2016 Aug; 354():i3518. PubMed ID: 27549763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID-19 in teriflunomide-treated patients with multiple sclerosis.
    Maghzi AH; Houtchens MK; Preziosa P; Ionete C; Beretich BD; Stankiewicz JM; Tauhid S; Cabot A; Berriosmorales I; Schwartz THW; Sloane JA; Freedman MS; Filippi M; Weiner HL; Bakshi R
    J Neurol; 2020 Oct; 267(10):2790-2796. PubMed ID: 32494856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ▼Teriflunomide for multiple sclerosis.
    Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aclidinium bromide, tofacitinib citrate, and teriflunomide.
    Hussar DA; Hurrey NJ
    J Am Pharm Assoc (2003); 2013; 53(1):106-10. PubMed ID: 23636164
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.